Selecta Biosciences (NASDAQ:SELB – Get Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.
Separately, Zacks Investment Research upgraded shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Selecta Biosciences currently has an average rating of “Buy” and a consensus target price of $5.45.
Shares of Selecta Biosciences stock opened at $0.73 on Friday. The company has a market cap of $110.76 million, a P/E ratio of -14.59 and a beta of 1.36. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.31 and a current ratio of 3.31. Selecta Biosciences has a one year low of $0.65 and a one year high of $5.28. The firm has a fifty day moving average of $1.15 and a two-hundred day moving average of $2.25.
Selecta Biosciences (NASDAQ:SELB – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.19. Selecta Biosciences had a net margin of 25.63% and a negative return on equity of 33.56%. During the same quarter in the prior year, the company posted ($0.22) earnings per share. As a group, equities analysts predict that Selecta Biosciences will post -0.28 earnings per share for the current year.
In 2018, economist Nomi Prins issued a dire warning to her readers. Now, she’s coming out with a new warning.
She says: “If you’re betting on a ‘return to normal’ you’re in for a rude awakening. We’re never returning to normal… but if you know what’s coming, ‘normal’ won’t be something you’ll want anymore.”
In related news, Director Timothy C. Barabe purchased 50,000 shares of the business’s stock in a transaction dated Monday, May 9th. The stock was acquired at an average price of $0.77 per share, for a total transaction of $38,500.00. Following the acquisition, the director now directly owns 250,013 shares of the company’s stock, valued at approximately $192,510.01. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 30.50% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC grew its stake in Selecta Biosciences by 1,035.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 211,612 shares of the company’s stock valued at $690,000 after acquiring an additional 192,975 shares during the last quarter. HighVista Strategies LLC acquired a new stake in Selecta Biosciences in the 3rd quarter valued at about $92,000. Capital Fund Management S.A. acquired a new stake in Selecta Biosciences in the 3rd quarter valued at about $263,000. Arrowstreet Capital Limited Partnership acquired a new stake in Selecta Biosciences in the 3rd quarter valued at about $773,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Selecta Biosciences in the 3rd quarter valued at about $2,116,000. 72.62% of the stock is currently owned by hedge funds and other institutional investors.
Selecta Biosciences Company Profile (Get Rating)
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Selecta Biosciences right now?
Before you consider Selecta Biosciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Selecta Biosciences wasn’t on the list.
While Selecta Biosciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: StockNews.com Downgrades Selecta Biosciences (NASDAQ:SELB) to Hold